- Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs
- Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia
- The company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptoms
- Tryp has announced two new collaborations for oversight of the drug trials this month; consultants with Fluence and Clinlogix will help to ensure the quality of the tests
Bioscience pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), pursuing its goal of developing psychedelic drug treatments for diseases that otherwise have unmet medical needs, is continuing to prepare for an upcoming Phase 2a clinical trial for treating eating disorders by forging partnerships with professionals experienced in conducting such trials.
The company’s recent announcement that it will collaborate with psychedelic therapy educational platform Fluence in a master service agreement to provide design and training for the psychotherapeutic portion of the upcoming trials follows on the heels of Tryp’s agreement with the University of Florida to conduct the clinical trial.
Pediatric medical researcher Jennifer Miller, M.D., of the University of Florida is leading the investigation into the potential of Tryp’s TRP-8802 psilocybin product for safety, pharmacokinetics and efficacy. Miller is an expert in certain eating disorders including binge eating and hyperphagia.
“There are currently no approved drugs and only limited options to treat patients with rare over-eating disorders,” Miller stated in a news release announcing the collaboration (https://ibn.fm/rSnYK).
The company’s upcoming Phase 2a trial for fibromyalgia patients is designed to provide an alternative treatment option for the large number of patients currently relying on opioids to relieve their symptoms.
Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients, according to another news release issued May 3 (https://ibn.fm/SO55k).
“In the fast-moving arena of psychedelic therapies, Fluence has established themselves as the leader in psychotherapy design and training,” Tryp President and Chief Science Officer Jim Gilligan stated in the news release. “Psychotherapy is an essential component of the effective administration of our innovative psilocybin formulations for the chronic pain and eating disorder indications that we are pursuing. Fluence’s experience with training hundreds of clinicians combined with the training protocol they are creating with Tryp will help create a safer and more effective treatment protocol for our clinical trials and ultimately for patients suffering from these conditions.”
Additionally, Tryp announced May 10 that Contract Research Organization (“CRO”) Clinlogix will provide support services for the upcoming Phase 2a trials (https://ibn.fm/V0Zr7). Clinlogix has developed experience in providing CRO services for the development of novel pharmaceutical products on a global basis, and the master service agreement between Tryp and Clinlogix will support the development of Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFNTM”) program, according to the announcement.
“The proper execution of a clinical study is of paramount importance in order to achieve clinical success; working with the team from Clinlogix provides Tryp with key elements needed for the conduct of a successful clinical study,” Gilligan added.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.